Posters
Acute effect of 5% hypertonic ophthalmic solutions on corneal thickness and densitometry after cataract surgery
Poster Details
First Author: A.Ataç TURKEY
Co Author(s): S. Sül
Abstract Details
Purpose:
To evaluate the acute effect of 5% hypertonic ophthalmic solution (HOS) drops on corneal thickness (CT) and corneal densitometry (CD) after phacoemulsification.
Setting:
Department of ophthalmology, Muğla Sıtkı Koçman University Faculty of Medicine
Methods:
32 eyes of 32 patients who underwent uncomplicated phacoemulsification were included in this study. Patients who had diseases such as diabetes, keratoconus, pseudoexfoliation, postoperative high intraocular pressure which could effect CT and CD measurements were not included. At the morning of postoperative day 1, CT and CET (central 2 mm and paracentral 2-5mm zone) and CD (central 2 mm and paracentral 2-6 mm zone) were assessed before and after HOS installation. CT and CET were evaluated with anterior segment optical coherence tomography (AS-OCT). Pentacam was used to evaluate CD.
Results:
Mean pre and postinstallation CT were 661±57µ and 646±55 µ (p=0.477) and mean pre and postinstallation CET were 59±6µ and 55±5µ in (p=0.134) in the central 2mm zone. The differences between pre and postinstallation CT and CET were also not significant in the paracentral 2-5 mm zone. The pre and postinstallation CD measurements at central 2 mm and paracentral 2-6 mm zone at anterior, central and posterior layers were not significantly different. (Central 2mm zone; anterior layer: 38.7±9 vs 34.8±9,p=0.255, central layer: 24.4±13 s 23.7±12,p=0.869, posterior layer: 18.5±8 vs 18.1±8, p=0.913).
Conclusions:
HOS drops seem to effect the corneal epithelium and anterior corneal stroma more than other layers of cornea in the acute period according to the AS-OCT and densitometry measurements. Acute effect of HOSs seem to be limited and repeated applications are required, because the differences between pre and postinstallation CT, CET and densitometry values are not significant.
Financial Disclosure:
None